Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lipoxin A5 (LXA5) is produced by enzymatic transformation of EPA by leukocytes. LXA5 slowly contracts pulmonary parenchymal strips from guinea pig with similar potency to that of LXA4 and LXB4. However, LXA5 does not exert the vasodilatory effects on aortic smooth muscle exhibited by LXA4 and LXB4.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 μg | 約 35 days | ¥ 160,500 |
50 μg | 約 35 days | ¥ 303,000 |
100 μg | 約 35 days | ¥ 574,000 |
説明 | Lipoxin A5 (LXA5) is produced by enzymatic transformation of EPA by leukocytes. LXA5 slowly contracts pulmonary parenchymal strips from guinea pig with similar potency to that of LXA4 and LXB4. However, LXA5 does not exert the vasodilatory effects on aortic smooth muscle exhibited by LXA4 and LXB4. |
分子量 | 350.45 |
分子式 | C20H30O5 |
CAS No. | 110657-98-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PBS (pH 7.2): 1 mg/mL
Ethanol: 50 mg/mL
DMF: 50 mg/mL
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lipoxin A5 110657-98-2 Lipoxin A-5 Inhibitor inhibitor inhibit